New Methods for Early Detection of Acute Kidney Injury After Heart Surgery

Sponsor
Karolinska Institutet (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03974347
Collaborator
(none)
200
32

Study Details

Study Description

Brief Summary

The investigators intend to study 2 new methods for the early detection of Acute Kidney Injury (AKI) after cardiac surgery and compare and combine the predictive abilities of these methods with established renal injury markers and epidemiological models to detect (AKI).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Acute Kidney Injury is common after Cardiac surgery and occurs in up to 20% of patients (Ref Rydén).

    This study will evaluate two new methods for the early detection of acute kidney injury in 200 patients undergoing elective cardiac surgery at the Karolinska Hospital.

    These methods are:
    1. Ultrasound based measurement of the kidneys blood flow profile measured using renal resistive index (RRI). This will be measured prior and within 4 hours post surgery. Ref Herzberg, Le Dorze.

    2. Urine creatinine clearance will be measured in the first four hours after cardiac surgery.

    The investigators will also measure known renal injury markers in blood and urine samples post operatively. These include Neutrophil gelatinise-associated lipocalin (NGAL), tissue inhibitor of metalloproteinases (TIMP-2), Insulin-like growth factor-binding protein 7 (IGFBP7), Kidney Injury Molecule 1 (KIM-1), Nephroclear, Interleukin 18 (IL-18), Fatty acid-binding protein (L-FABP), Fibulin-1, cystatin C och albumin.

    The new methods of AKI detection will be used to build a statistical model to predict AKI after cardiac surgery. We will determine whether the addition of renal injury markers and epidemiological factors known to be associated with the development of AKI (variables such as age, known chronic renal dysfunction or heart failure) can improve precision in diagnosis.

    AKI will be defined by the Kidney Disease improving Global outcomes (KDIGO) criteria (Ref KDIGO KDIGO Clinical Practice Guideline for Acute Kidney Injury, Khwaja A).

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    New Methods for Early Detection of Acute Kidney Injury After Heart Surgery
    Anticipated Study Start Date :
    Jan 1, 2023
    Anticipated Primary Completion Date :
    Sep 1, 2024
    Anticipated Study Completion Date :
    Sep 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Acute kidney injury, no acute kidney injury

    Acute kidney injury after cardiac surgery will be defined by KDIGO criteria, Creatinine rise from baseline and or urine production.

    No Acute Kidney Injury

    No Acute kidney Injury after Cardiac surgery, according to KDIGO AKI definition

    Outcome Measures

    Primary Outcome Measures

    1. Acute Kidney Injury [48 hours]

      Acute Kidney Injury defined by KDiGO criteria

    Secondary Outcome Measures

    1. 30 day Mortality [30 days]

      Death occurring up to 30 days after cardiac surgery

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18 years and older

    • Undergoing elective cardiac surgery (Coronary artery bypass grafting, valve surgery, aortic surgery or a combination).

    • Able to understand and give written consent to partake in the study

    Exclusion Criteria:
    • Unable to give consent

    • Previously received a renal transplant

    • Renal failure requiring dialysis prior to surgery

    • Persistent atrial fibrillation

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Karolinska Institutet

    Investigators

    • Principal Investigator: Max Bell, MD, PHD, Karolinska Institutet
    • Study Director: Daniel Hertberg, MD, PHD, Karolinska Institutet

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Max Bell, Associate Professor, Karolinska Institutet
    ClinicalTrials.gov Identifier:
    NCT03974347
    Other Study ID Numbers:
    • 2019-02319
    First Posted:
    Jun 4, 2019
    Last Update Posted:
    Aug 18, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Max Bell, Associate Professor, Karolinska Institutet
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 18, 2022